|
Video: What is a Stock Split?
|
|
Aura Biosciences is a clinical-stage biotechnology company using its targeted oncology platform to develop a potential new standard of care across various cancer indications, with an initial focus on ocular and urologic oncology. Co.'s proprietary platform enables the targeting of a range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDC). AU-011, Co.'s VDC candidate, is being developed for the first line treatment of primary choroidal melanoma. In addition, Co. is developing AU-011 for the treatment of non-muscle invasive bladder cancer. According to our AURA split history records, Aura Biosciences has had 0 splits. | |
|
Aura Biosciences (AURA) has 0 splits in our AURA split history database.
Looking at the AURA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aura Biosciences shares, starting with a $10,000 purchase of AURA, presented on a split-history-adjusted basis factoring in the complete AURA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/01/2021 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$15.30 |
|
End price/share: |
$7.85 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-48.69% |
|
Average Annual Total Return: |
-24.23% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,130.19 |
|
Years: |
2.41 |
|
|
|
|
|